granzyme

3,4 Dichloroisocoumarin is a granzyme, cathepsin G, and neutrolphil elastase inhibitor

Ac-IETD-CHO TFA is a granzyme B and caspase-8 inhibitor that inhibits caspase8 activity by blocking caspase3 precursor cleavage.Ac-IETD-CHO TFA inhibits Fas-mediated apoptosis.

Compound Lup-20(29)-en-3-yl acetate, a derivative of Lupeol, inhibits the progression of rheumatoid arthritis by downregulating TNF-α, IL-1β, MCP-1, COX-2, VEGF and granzyme B.

DdBIC is a pyroptosis inducer that associates with Nur77, facilitating its translocation to the mitochondria. This interaction activates the depletion of SDHA succinyl-CoA, disrupts hemeostasis, causes electron leakage, and stimulates mitochondrial ROS generation. Mitochondrial ROS, induced by DdBIC, oxidatively activates OMA1, leading to OPA1 cleavage and release into the cytoplasm, triggering the PERK-activated integrated stress response, ultimately activating granzyme B (granzyme B) to cleave GSDMC. DdBIC is applicable in melanoma research.

Antitumor agent-210 (Compound 1778) acts as an NK cell activator. It weakly enhances the proliferation of NK 92 cells and significantly boosts their activation and degranulation, thereby increasing their ability to kill tumor cells. Additionally, Antitumor agent-210 stimulates the release of cytokines granzyme B, perforin, and IFN-γ. It also reduces the number of metastatic lesions in mouse lungs and can be utilized in studies of melanoma lung metastasis.

Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a cell-permeable, irreversible inhibitor specific for caspase-8. Z-IETD-FMK also an inhibitor of granzyme B. Z-IETD-FMK exhibits cell permeability. Z-IETD-FMK can be used in studies of the extrinsic apoptosis pathway, pyroptosis, and programmed necrosis.

Ac-IETD-CHO is a potent, reversible inhibitor of granzyme B and caspase 8, which also impedes Fas-mediated apoptosis, hemorrhagic conditions, and liver failure. Furthermore, this compound hampers cell death induced by cytotoxic T lymphocytes [1] [2].

Z-Ala-Ala-Asp-CMK (Z-AAD-CMK) is a selective granzyme B inhibitor that blocks granzyme B protease activity, suitable for studies in inflammatory diseases and tumours.

Anti-Mouse 4-1BB/CD137 Antibody (3H3) is a monoclonal inhibitory antibody targeting mouse 4-1BB/CD137. It can effectively activate memory T cells and exert anti-tumor effects by upregulating the expression levels of Bcl-xL and granzyme B, and is applicable to research on various tumors such as lymphoma and colon cancer.

ERY-974 is a T cell-redirecting bispecific antibody (TCB) targeting GPC3. It binds to both GPC3 and the CD3 receptor on the surface of T cells, activating them to release perforin and granzyme, which induces apoptosis in tumor cells. ERY-974 shows potential for research in solid tumors, such as liver cancer.

Lupeol acetate is a derivative of Lupeol with anti-cancer, anti-inflammatory, anti-diabetic, anti-snake venom, anti-fertility effects and oral activity. It is able to inhibit rheumatoid arthritis by down-regulating inflammatory cytokines (TNF-α, IL-1β, MCP-1, COX-2, VEGF, granzyme B) and is cytotoxic to Hep-3B and A549 cells.

Ac-IEPD-AFC (IEPD) is a fluorescent substrate for granzyme B and can be used to measure granzyme B activity.

Ac-IEPD-CHO, a granzyme B inhibitor, is applicable in cancer research [1].

Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic polypeptide targeting CXCR4, known for its significant anticancer properties. It inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and the development of lung metastasis, offering better serum stability and higher CXCR4 affinity (IC50=20 nM) compared to the lead compound. Peptide R54 works synergistically with anti-PD-1 therapy to exhibit antitumor effects in vivo, enhancing granzyme activity and reducing Foxp3 cell infiltration. It is useful for research in colon cancer, ovarian cancer, and melanoma.

Ac-KVPL-CMKTFA is the trifluoroacetate salt form of Ac-KVPL-CMK, a specific inhibitor targeting Granzyme M (GrM). Ac-KVPL-CMK significantly inhibits GrM-mediated tumor cell death and reduces the cytotoxic activity of LAK cells against HeLa cells. This compound is applicable for cancer research.

Ac-KVPL-CMK is a specific inhibitor targeting granzyme M (GrM). It significantly suppresses GrM-mediated tumor cell death and reduces the cytotoxic activity of LAK cells against HeLa cells. Ac-KVPL-CMK is applicable in cancer research.